

F D F

DOSSIER
UNDER DEVELOPMENT



DOSSIERS UNDER DEVELOPMENT

Product name	Pharmaceutical form	Strength	Reference	Therapeutic class	Dossier availability
ALIMENTARY TRACT & METABOLISM					
1. Sitagliptin hydrochloride NEW!	Film-coated tablets	25 mg 50 mg 100 mg	Januvia / Merck	Oral antidiabetic	2017 Q4
2. Sitagliptin hydrochloride + Metformin NEW!	Film-coated tablets	50 mg + 500 mg 50 mg + 850 mg 50 mg + 1000 mg	Januvia / Merck	Oral antidiabetic	2018 Q1
ANTINEOPLASTIC & IMMUNOMODULATING AGENTS					
3. Lenalidomide	Capsules	2.5 mg 5 mg 7.5 mg 10 mg 15 mg 25 mg	Revlimid / Celgene	Multiple myeloma	2018 Q2
BLOOD & BLOOD FORMING ORGANS					
4. Rivaroxaban *	Film-coated tablets	2.5 mg 10 mg 15 mg 20 mg	Xarelto / Bayer	Oral anticoagulant	2017 Q4
5. Ticagrelor **	Film-coated tablets	60 mg 90 mg	Brilique / AstraZeneca	Platelet aggregation inhibitor	2018 Q1
CARDIOVASCULAR SYSTEM					
6. Ramipril + Indapamide	Tablets	5 mg + 1.5 mg 10 mg + 1.5 mg	---	ACE inhibitor & diuretic combination	2017 Q2
7. Amlodipine maleate + Valsartan + Hydrochlorothiazide *	Film-coated tablets	5 mg + 160 mg + 12.5 mg 5 mg + 160 mg + 25 mg 10 mg + 160 mg + 12.5 mg 10 mg + 160 mg + 25mg 10 mg + 320 mg + 25 mg	Exforge HCT / Novartis	Calcium-channel blocker & angiotensin-II antagonist & diuretic combination	2017 Q3
NERVOUS SYSTEM					
8. Dimethyl fumarate	Gastro-resistant hard capsules	120 mg 240 mg	Tecfidera / Biogen Idec	Multiple sclerosis	2018 Q2
OPHTHALMOLOGICALS					
9. Bimatoprost + Timolol	Eye drops solution without preservatives	(0.3 mg + 5 mg) /ml	Ganfort / Allergan	Miotic & antiglaucoma	2017 Q3
RESPIRATORY SYSTEM					
10. Montelukast sodium	Chewable tablets	4 mg 5 mg	Singulair / Merck	Asthma treatment	2017 Q2

* Polpharma Group API

** Polpharma Group API + US dossier available

For more information and up-dates regarding available dossiers and dossiers in development, please contact your assigned Sales Manager or our Commercial Department. Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries.

Last update: January 2017

CONTACT

POLPHARMA GROUP PHARMACEUTICAL WORKS

Pelplińska 19
83-200 Starogard Gdański
Poland
Phone: +48 58 563 16 00
Fax: +48 58 562 23 53
www.polpharma.pl

POLPHARMA B2B STRATEGIC PARTNER, FARMAPROJECTS

Santa Eulàlia 240-242
08902 · L'Hospitalet de Llobregat
Barcelona (Spain)
Phone: +34 93 508 05 00
Fax: +34 93 508 05 01
e-mail: salesB2B@polpharma.com
www.polpharmab2b.com

